STOCK TITAN

[Form 4] Hewlett Packard Enterprise Company Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Positive)
Form Type
4
Rhea-AI Filing Summary

Tharimmune, Inc. (THAR) – Form 4 filing dated 07/07/2025

Director Kelly Anderson reported the award of 6,300 shares of common stock on 06/23/2025. The shares were granted at $0.00 cost under the company’s 2023 Omnibus Equity Incentive Plan and are held directly. No derivative securities were reported. Following the transaction, Anderson’s beneficial ownership stands at 6,300 common shares.

The filing does not disclose any sales, option exercises, or purchases with cash consideration, and it contains no financial performance information. Given the small size of the award and absence of market-moving details, the transaction appears routine and is unlikely to materially affect the company’s valuation or share liquidity.

Tharimmune, Inc. (THAR) – Comunicazione Form 4 datata 07/07/2025

Il direttore Kelly Anderson ha segnalato la concessione di 6.300 azioni ordinarie in data 23/06/2025. Le azioni sono state assegnate a un costo di $0,00 nell’ambito del Piano Omnibus di Incentivi Azionari 2023 della società e sono detenute direttamente. Non sono stati riportati titoli derivati. A seguito della transazione, la proprietà effettiva di Anderson ammonta a 6.300 azioni ordinarie.

La comunicazione non indica vendite, esercizi di opzioni o acquisti con pagamento in contanti, né contiene informazioni sulle performance finanziarie. Considerata la dimensione ridotta dell’assegnazione e l’assenza di dettagli rilevanti per il mercato, l’operazione sembra di routine e probabilmente non influirà in modo significativo sulla valutazione della società o sulla liquidità delle azioni.

Tharimmune, Inc. (THAR) – Presentación del Formulario 4 con fecha 07/07/2025

El director Kelly Anderson informó la adjudicación de 6,300 acciones ordinarias el 23/06/2025. Las acciones fueron otorgadas a un costo de $0.00 bajo el Plan Omnibus de Incentivos de Capital 2023 de la empresa y se mantienen directamente. No se reportaron valores derivados. Tras la transacción, la propiedad beneficiaria de Anderson asciende a 6,300 acciones ordinarias.

La presentación no revela ventas, ejercicios de opciones ni compras con pago en efectivo, ni contiene información sobre el desempeño financiero. Dado el tamaño reducido de la adjudicación y la ausencia de detalles que muevan el mercado, la transacción parece rutinaria y es poco probable que afecte materialmente la valoración de la empresa o la liquidez de sus acciones.

Tharimmune, Inc. (THAR) – 2025년 7월 7일자 Form 4 제출

이사 Kelly Anderson가 2025년 6월 23일에 6,300주 보통주 부여를 보고했습니다. 해당 주식은 회사의 2023년 종합 주식 인센티브 플랜에 따라 0.00달러 비용으로 부여되었으며 직접 보유 중입니다. 파생 증권은 보고되지 않았습니다. 이 거래 후 Anderson의 실질 소유 지분은 6,300주 보통주입니다.

제출서에는 매도, 옵션 행사 또는 현금 대가를 동반한 매입 내역이 없으며, 재무 성과 정보도 포함되어 있지 않습니다. 소규모 부여와 시장에 영향을 줄 만한 정보가 없다는 점에서 이번 거래는 일상적인 것으로 보이며, 회사 가치 평가나 주식 유동성에 중대한 영향을 미칠 가능성은 낮습니다.

Tharimmune, Inc. (THAR) – Dépôt du formulaire 4 daté du 07/07/2025

Le directeur Kelly Anderson a déclaré l’attribution de 6 300 actions ordinaires le 23/06/2025. Les actions ont été accordées à un coût de 0,00 $ dans le cadre du Plan d’Incitation Globale en Actions 2023 de la société et sont détenues directement. Aucun titre dérivé n’a été signalé. Suite à cette transaction, la propriété bénéficiaire d’Anderson s’élève à 6 300 actions ordinaires.

Le dépôt ne mentionne aucune vente, exercice d’options ou achat avec contrepartie en espèces, et ne contient aucune information sur la performance financière. Compte tenu de la faible taille de l’attribution et de l’absence de détails susceptibles d’influencer le marché, la transaction semble routinière et ne devrait pas affecter de manière significative la valorisation de la société ni la liquidité des actions.

Tharimmune, Inc. (THAR) – Form 4 Einreichung vom 07.07.2025

Direktor Kelly Anderson meldete die Zuteilung von 6.300 Stammaktien am 23.06.2025. Die Aktien wurden zu Kosten von 0,00 $ im Rahmen des Omnibus Equity Incentive Plans 2023 des Unternehmens gewährt und werden direkt gehalten. Es wurden keine derivativen Wertpapiere gemeldet. Nach der Transaktion beläuft sich Andersons wirtschaftliches Eigentum auf 6.300 Stammaktien.

Die Meldung enthält keine Angaben zu Verkäufen, Ausübung von Optionen oder Käufen gegen Barzahlung und keine finanziellen Leistungsdaten. Aufgrund der geringen Größe der Zuteilung und des Fehlens marktbewegender Details erscheint die Transaktion routinemäßig und wird voraussichtlich keine wesentlichen Auswirkungen auf die Unternehmensbewertung oder die Aktienliquidität haben.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine director share grant; immaterial to valuation, modest alignment with shareholders.

The Form 4 shows a standard equity incentive grant of 6,300 shares to Director Kelly Anderson at no cost, reinforcing board-level ownership without cash outlay. The award is small and does not signal insider buying conviction or liquidity pressure. No derivative positions or sales were disclosed, suggesting stable insider posture. Given the likely negligible percentage of total shares outstanding, I view the disclosure as neutral to the investment thesis and not impactful for the stock.

Tharimmune, Inc. (THAR) – Comunicazione Form 4 datata 07/07/2025

Il direttore Kelly Anderson ha segnalato la concessione di 6.300 azioni ordinarie in data 23/06/2025. Le azioni sono state assegnate a un costo di $0,00 nell’ambito del Piano Omnibus di Incentivi Azionari 2023 della società e sono detenute direttamente. Non sono stati riportati titoli derivati. A seguito della transazione, la proprietà effettiva di Anderson ammonta a 6.300 azioni ordinarie.

La comunicazione non indica vendite, esercizi di opzioni o acquisti con pagamento in contanti, né contiene informazioni sulle performance finanziarie. Considerata la dimensione ridotta dell’assegnazione e l’assenza di dettagli rilevanti per il mercato, l’operazione sembra di routine e probabilmente non influirà in modo significativo sulla valutazione della società o sulla liquidità delle azioni.

Tharimmune, Inc. (THAR) – Presentación del Formulario 4 con fecha 07/07/2025

El director Kelly Anderson informó la adjudicación de 6,300 acciones ordinarias el 23/06/2025. Las acciones fueron otorgadas a un costo de $0.00 bajo el Plan Omnibus de Incentivos de Capital 2023 de la empresa y se mantienen directamente. No se reportaron valores derivados. Tras la transacción, la propiedad beneficiaria de Anderson asciende a 6,300 acciones ordinarias.

La presentación no revela ventas, ejercicios de opciones ni compras con pago en efectivo, ni contiene información sobre el desempeño financiero. Dado el tamaño reducido de la adjudicación y la ausencia de detalles que muevan el mercado, la transacción parece rutinaria y es poco probable que afecte materialmente la valoración de la empresa o la liquidez de sus acciones.

Tharimmune, Inc. (THAR) – 2025년 7월 7일자 Form 4 제출

이사 Kelly Anderson가 2025년 6월 23일에 6,300주 보통주 부여를 보고했습니다. 해당 주식은 회사의 2023년 종합 주식 인센티브 플랜에 따라 0.00달러 비용으로 부여되었으며 직접 보유 중입니다. 파생 증권은 보고되지 않았습니다. 이 거래 후 Anderson의 실질 소유 지분은 6,300주 보통주입니다.

제출서에는 매도, 옵션 행사 또는 현금 대가를 동반한 매입 내역이 없으며, 재무 성과 정보도 포함되어 있지 않습니다. 소규모 부여와 시장에 영향을 줄 만한 정보가 없다는 점에서 이번 거래는 일상적인 것으로 보이며, 회사 가치 평가나 주식 유동성에 중대한 영향을 미칠 가능성은 낮습니다.

Tharimmune, Inc. (THAR) – Dépôt du formulaire 4 daté du 07/07/2025

Le directeur Kelly Anderson a déclaré l’attribution de 6 300 actions ordinaires le 23/06/2025. Les actions ont été accordées à un coût de 0,00 $ dans le cadre du Plan d’Incitation Globale en Actions 2023 de la société et sont détenues directement. Aucun titre dérivé n’a été signalé. Suite à cette transaction, la propriété bénéficiaire d’Anderson s’élève à 6 300 actions ordinaires.

Le dépôt ne mentionne aucune vente, exercice d’options ou achat avec contrepartie en espèces, et ne contient aucune information sur la performance financière. Compte tenu de la faible taille de l’attribution et de l’absence de détails susceptibles d’influencer le marché, la transaction semble routinière et ne devrait pas affecter de manière significative la valorisation de la société ni la liquidité des actions.

Tharimmune, Inc. (THAR) – Form 4 Einreichung vom 07.07.2025

Direktor Kelly Anderson meldete die Zuteilung von 6.300 Stammaktien am 23.06.2025. Die Aktien wurden zu Kosten von 0,00 $ im Rahmen des Omnibus Equity Incentive Plans 2023 des Unternehmens gewährt und werden direkt gehalten. Es wurden keine derivativen Wertpapiere gemeldet. Nach der Transaktion beläuft sich Andersons wirtschaftliches Eigentum auf 6.300 Stammaktien.

Die Meldung enthält keine Angaben zu Verkäufen, Ausübung von Optionen oder Käufen gegen Barzahlung und keine finanziellen Leistungsdaten. Aufgrund der geringen Größe der Zuteilung und des Fehlens marktbewegender Details erscheint die Transaktion routinemäßig und wird voraussichtlich keine wesentlichen Auswirkungen auf die Unternehmensbewertung oder die Aktienliquidität haben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
rahim rami

(Last) (First) (Middle)
1701 E MOSSY OAKS ROAD

(Street)
SPRING TX 77389

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Hewlett Packard Enterprise Co [ HPE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Pres GM Networking
3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/02/2025 M 123,931(1) A $21.25 123,931 D
Common Stock 07/02/2025 F 65,250 D $21.25 58,681 D
Common Stock 07/02/2025 M 346,255(1) A $21.25 404,936 D
Common Stock 07/02/2025 F 182,305 D $21.25 222,631 D
Common Stock 07/02/2025 M 65,631(1) A $21.25 288,262 D
Common Stock 07/02/2025 F 34,555 D $21.25 253,707 D
Common Stock 455 I Living Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (2) 07/02/2025 A 123,931(1)(3) (3) (3) Common Stock 123,931 (3) 123,931 D
Restricted Stock Units (2) 07/02/2025 M 123,931 (3) (3) Common Stock 123,931 (3) 0 D
Performance Stock Unit (2) 07/02/2025 A 346,255(1)(4) (4) (4) Common Stock 346,255 (4) 346,255 D
Performance Stock Unit (2) 07/02/2025 M 346,255 (4) (4) Common Stock 346,255 (4) 0 D
Restricted Stock Units (2) 07/02/2025 A 218,800(1)(5) (5) (5) Common Stock 218,800 (5) 218,800 D
Restricted Stock Units (2) 07/02/2025 M 65,631 (5) (5) Common Stock 65,631 (5) 153,169 D
Restricted Stock Units (2) 07/02/2025 A 308,311(1)(6) (6) (6) Common Stock 308,311 (6) 308,311 D
Restricted Stock Units (2) 07/02/2025 A 394,379(1)(7) (7) (7) Common Stock 394,379 (7) 394,379 D
Restricted Stock Units (2) 07/02/2025 A 394,379(1)(8) (8) (8) Common Stock 394,379 (8) 394,379 D
Employee Stock Option (right to buy) $16.02 07/02/2025 A 589,830(1)(9) (9) 02/18/2029(9) Common Stock 589,830 (9) 589,830 D
Explanation of Responses:
1. As reported in the Agreement and Plan of Merger filed by Issuer with the SEC on 01/10/24, certain equity-based awards originally granted to the reporting person by Juniper Networks, Inc. ("Juniper") were converted on 07/02/25 ("Closing") to Issuer's equity awards to preserve the aggregate intrinsic value of the original award as measured immediately before the merger. The adjusted equity award is subject to the same terms and conditions as the original Juniper awards, unless otherwise noted. The reporting person's equity-based awards reflect that conversion adjustment.
2. Each restricted stock unit and performance stock unit ("PSU") represent a contingent right to receive one share of Issuer's common stock.
3. On 07/02/25, the reporting person's 02/20/23 equity award was converted into 123,931 restricted stock units ("RSUs"), all of which vested at Closing.
4. On 07/02/25, the reporting person's 02/20/23 PSU equity award was converted into 346,255 performance stock units, all of which vested at Closing.
5. On 07/02/25, the reporting person's 02/20/24 equity award was converted into 218,800 RSUs, 65,631 of which vested on 07/02/25, 43,769 of which will vest on 02/20/26, and 109,400 of which will vest on 07/03/26.
6. On 07/02/25, the reporting person's 02/20/24 PSU equity award was converted into 308,311 RSUs, all of which will vest on 07/03/26.
7. On 07/02/25, the reporting person's 02/20/25 equity award was converted into 394,379 RSUs, 134,089 of which will vest on 02/20/26, and 260,290 of which will vest on 07/03/26.
8. On 07/02/25, the reporting person's 06/20/25 PSU equity award was converted into 394,379 RSUs, all of which will vest on 07/03/26.
9. On 07/02/25, the reporting person's 02/18/22 fully vested non-qualified stock options were converted into 589,830 non-qualified stock options. The option is no longer exercisable beginning on this date.
Ki Hoon Kim as Attorney-in-Fact for Rami Rahim 07/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did THAR report on the 07/07/2025 Form 4?

Director Kelly Anderson received 6,300 shares of common stock on 06/23/2025 under the 2023 Omnibus Equity Incentive Plan.

Was there any cash consideration for the 6,300 THAR shares?

No. The shares were granted at $0.00 as an equity incentive award.

How many THAR shares does Kelly Anderson own after the grant?

Following the transaction, Anderson beneficially owns 6,300 common shares, all held directly.

Did the Form 4 include any sales or option exercises by the director?

No. The filing reports only an acquisition of common stock; there were no sales or derivative transactions.

Does this Form 4 filing materially affect Tharimmune’s share count?

The award is relatively small; based on the information provided, it is unlikely to materially impact the total shares outstanding.
Hewlett Packard Enterprise Co

NYSE:HPE

HPE Rankings

HPE Latest News

HPE Latest SEC Filings

HPE Stock Data

27.29B
1.31B
0.44%
85.93%
2.28%
Communication Equipment
Computer & Office Equipment
Link
United States
SPRING